To amend the Public Health Service Act to establish an Office of Drug Manufacturing.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To amend the Public Health Service Act to establish an Office of Drug Manufacturing., changes federal law or congressional policy affecting federal agencies and legislative administrators. The main policy domain is Government Operations, Healthcare, Trade.
Who Benefits and How
federal agencies and legislative administrators may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section S1: 1. Short title This Act may be cited as the Affordable Drug Manufacturing Act of 2023.
- Section id3a0fb1918b77497ba31e3d0b0655a50a: 2. Public manufacturing of pharmaceuticals Part A of title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by adding at the end the...
- Section id83f83e7d815e4d0c842d3f105700af61: 310C. Manufacturing of drugs There is established within the Department of Health and Human Services an office to be known as the Office of Drug Manufacturing...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To amend the Public Health Service Act to establish an Office of Drug Manufacturing., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Key Policy Areas
Government Operations, Healthcare, Trade
Primary Purpose
This bill, To amend the Public Health Service Act to establish an Office of Drug Manufacturing., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Policy Domains
Whole bill
Identified Gains
- federal agencies and legislative administrators
Identified Costs
- federal implementing agencies
Sponsors
Legislative Progress
IntroducedMs. Warren (for herself and Mr. Merkley) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
Key Definitions
Terms defined in this bill
any entity that is currently— a drug manufacturer
any entity that is currently— a drug manufacturer
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology